<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04550195</url>
  </required_header>
  <id_info>
    <org_study_id>IM037-009</org_study_id>
    <secondary_id>2019-004518-32</secondary_id>
    <nct_id>NCT04550195</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy Participants</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study of the Safety and Tolerability, and Pharmacokinetics (Including Food Effect, pH Effect and Japanese Bridging Study) of BMS-986337 Following Oral Administration in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and drug levels of&#xD;
      BMS-986337 in healthy participants and in healthy Japanese participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 14, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 29, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 81 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes in clinical laboratory values: Hematology tests</measure>
    <time_frame>Up to 51 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes in clinical laboratory values: Urinalysis tests</measure>
    <time_frame>Up to 51 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes in clinical laboratory values: Clinical chemistry tests</measure>
    <time_frame>Up to 51 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes from baseline in vital signs: Heart Rate</measure>
    <time_frame>Up to 51 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes from baseline in vital signs: Body Temperature</measure>
    <time_frame>Up to 51 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes from baseline in vital signs: Blood Pressure</measure>
    <time_frame>Up to 51 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes from baseline in vital signs: Respiratory Rate</measure>
    <time_frame>Up to 51 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes in electrocardiogram (ECG) parameters: Heart rate (HR)</measure>
    <time_frame>Up to 51 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes from baseline in physical examinations</measure>
    <time_frame>Up to 51 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes in ECG parameters: PR interval</measure>
    <time_frame>Up to 51 days</time_frame>
    <description>PR interval is the time from the onset of the P wave to the start of the QRS complex</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes in ECG parameters: QRS duration</measure>
    <time_frame>Up to 51 days</time_frame>
    <description>QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes in ECG parameters: QTc-interval (Fridericia's)</measure>
    <time_frame>Up to 51 days</time_frame>
    <description>QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes in ECG parameters: QT interval</measure>
    <time_frame>Up to 51 days</time_frame>
    <description>The QT interval is the time from the start of the Q wave to the end of the T wave.</description>
  </primary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part A Single Ascending Dose (SAD) Cohort A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A SAD Cohort A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A SAD Cohort A3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A SAD Cohort A4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A SAD Cohort A5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A SAD Cohort A6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Multiple Ascending Dose (MAD) Cohort B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B MAD Cohort B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B MAD Cohort B3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B MAD Cohort B4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C MAD in Japanese Healthy participants Cohort C1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C MAD in Japanese Healthy participants Cohort C2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C MAD in Japanese Healthy participants Cohort C3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986337</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Part A SAD Cohort A2</arm_group_label>
    <arm_group_label>Part A SAD Cohort A3</arm_group_label>
    <arm_group_label>Part A SAD Cohort A4</arm_group_label>
    <arm_group_label>Part A SAD Cohort A5</arm_group_label>
    <arm_group_label>Part A SAD Cohort A6</arm_group_label>
    <arm_group_label>Part A Single Ascending Dose (SAD) Cohort A1</arm_group_label>
    <arm_group_label>Part B MAD Cohort B2</arm_group_label>
    <arm_group_label>Part B MAD Cohort B3</arm_group_label>
    <arm_group_label>Part B MAD Cohort B4</arm_group_label>
    <arm_group_label>Part B Multiple Ascending Dose (MAD) Cohort B1</arm_group_label>
    <arm_group_label>Part C MAD in Japanese Healthy participants Cohort C1</arm_group_label>
    <arm_group_label>Part C MAD in Japanese Healthy participants Cohort C2</arm_group_label>
    <arm_group_label>Part C MAD in Japanese Healthy participants Cohort C3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>BMS-986337 Placebo</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Part A SAD Cohort A2</arm_group_label>
    <arm_group_label>Part A SAD Cohort A3</arm_group_label>
    <arm_group_label>Part A SAD Cohort A4</arm_group_label>
    <arm_group_label>Part A SAD Cohort A5</arm_group_label>
    <arm_group_label>Part A Single Ascending Dose (SAD) Cohort A1</arm_group_label>
    <arm_group_label>Part B MAD Cohort B2</arm_group_label>
    <arm_group_label>Part B MAD Cohort B3</arm_group_label>
    <arm_group_label>Part B MAD Cohort B4</arm_group_label>
    <arm_group_label>Part B Multiple Ascending Dose (MAD) Cohort B1</arm_group_label>
    <arm_group_label>Part C MAD in Japanese Healthy participants Cohort C1</arm_group_label>
    <arm_group_label>Part C MAD in Japanese Healthy participants Cohort C2</arm_group_label>
    <arm_group_label>Part C MAD in Japanese Healthy participants Cohort C3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Famotidine</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Part A SAD Cohort A6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  No clinically significant deviation from normal in medical history, physical&#xD;
             examination, electrocardiograms (ECGs), and clinical laboratory determinations&#xD;
&#xD;
          -  For Japanese cohorts in Part C, must be first-generation Japanese (born in Japan, not&#xD;
             living outside of Japan for more than 10 years, and both parents are ethnically&#xD;
             Japanese)&#xD;
&#xD;
          -  Body mass index (BMI) of 18.0 kg/m^2 to 30.0 kg/m^2, inclusive, at screening; BMI =&#xD;
             weight (kg)/height (m)^2&#xD;
&#xD;
          -  Women and men must agree to follow specific methods of contraception, if applicable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are of childbearing potential&#xD;
&#xD;
          -  Women who are breastfeeding&#xD;
&#xD;
          -  Prior exposure to BMS-986278&#xD;
&#xD;
          -  Positive nasopharyngeal reverse transcriptase polymerase chain reaction (RT-PCR) test&#xD;
             for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on Day -2&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

